Investigational Drug Information for Navitoclax
✉ Email this page to a colleague
What is the drug development status for Navitoclax?
Navitoclax is an investigational drug.
There have been 29 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 31st 2020.
The most common disease conditions in clinical trials are Leukemia, Lymphoid, Neoplasms, and Leukemia. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.
There are four hundred and fifteen US patents protecting this investigational drug and four international patents.
Summary for Navitoclax
| US Patents | 415 |
| International Patents | 4,521 |
| US Patent Applications | 1,342 |
| WIPO Patent Applications | 857 |
| Japanese Patent Applications | 336 |
| Clinical Trial Progress | Phase 2 (2020-08-31) |
| Vendors | 98 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Fight Kids Cancer | Phase 1/Phase 2 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | IBFM | Phase 1/Phase 2 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Innovative Therapies For Children with Cancer Consortium | Phase 1/Phase 2 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | ⤷ Try a Trial | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Try a Trial |
| Navitoclax | ⤷ Try a Trial | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Try a Trial |
| Navitoclax | ⤷ Try a Trial | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | ⤷ Try a Trial |
| Navitoclax | ⤷ Try a Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try a Trial |
| Navitoclax | ⤷ Try a Trial | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | University of Georgia Research Foundation Inc. (Athens, GA) | ⤷ Try a Trial |
| Navitoclax | ⤷ Try a Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Australia | AU2012322660 | 2031-10-11 | ⤷ Try a Trial |
| Navitoclax | Australia | AU2017228527 | 2031-10-11 | ⤷ Try a Trial |
| Navitoclax | Canada | CA2851788 | 2031-10-11 | ⤷ Try a Trial |
| Navitoclax | Canada | CA3173988 | 2031-10-11 | ⤷ Try a Trial |
| Navitoclax | European Patent Office | EP2766355 | 2031-10-11 | ⤷ Try a Trial |
| Navitoclax | European Patent Office | EP3799871 | 2031-10-11 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
